Edition:
United States

Flexion Therapeutics Inc (FLXN.OQ)

FLXN.OQ on NASDAQ Stock Exchange Global Market

24.73USD
20 Apr 2018
Change (% chg)

$-0.36 (-1.43%)
Prev Close
$25.09
Open
$24.98
Day's High
$25.13
Day's Low
$24.37
Volume
247,514
Avg. Vol
285,997
52-wk High
$32.22
52-wk Low
$16.51

Chart for

About

Flexion Therapeutics, Inc. is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company's lead product... (more)

Overall

Beta: 0.84
Market Cap(Mil.): $991.65
Shares Outstanding(Mil.): 37.62
Dividend: --
Yield (%): --

Financials

  FLXN.OQ Industry Sector
P/E (TTM): -- 185.16 33.25
EPS (TTM): -4.11 -- --
ROI: -44.39 -0.71 13.13
ROE: -61.47 -2.76 14.96

BRIEF-Flexion Therapeutics Reports Q4 Sales $355,000

* FLEXION THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

Mar 08 2018

BRIEF-Flexion Therapeutics Announces Initial Data From Clinical Trial Evaluating Repeat Administration Of Zilretta

* FLEXION THERAPEUTICS ANNOUNCES INITIAL DATA FROM CLINICAL TRIAL EVALUATING REPEAT ADMINISTRATION OF ZILRETTA™ (TRIAMCINOLONE ACETONIDE EXTENDED-RELEASE INJECTABLE SUSPENSION)

Jan 08 2018

BRIEF-Flexion Therapeutics Enrolls First Patient In Phase 2 Pharmacokinetics And Safety Study Of Zilretta

* FLEXION THERAPEUTICS ENROLLS FIRST PATIENT IN PHASE 2 PHARMACOKINETICS AND SAFETY STUDY OF ZILRETTA™ (TRIAMCINOLONE ACETONIDE EXTENDED-RELEASE INJECTABLE SUSPENSION) IN BILATERAL OSTEOARTHRITIS OF THE KNEE Source text for Eikon: Further company coverage:

Dec 07 2017

BRIEF-Flexion therapeutics reports third-quarter results

* Flexion Therapeutics reports third-quarter 2017 financial results and recent business highlights

Nov 06 2017

Earnings vs. Estimates